Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. (PL:SVE)
:SVE
Want to see PL:SVE full AI Analyst Report?
Total Valuation
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. has a market cap or net worth of zł227.68M. The enterprise value is zł311.04M.
Market Capzł227.68M
Enterprise Valuezł311.04M
Share Statistics
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. has 76,019,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding76,019,400
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.’s return on equity (ROE) is -0.16 and return on invested capital (ROIC) is -6.83%.
Return on Equity (ROE)-0.16
Return on Assets (ROA)-0.07
Return on Invested Capital (ROIC)-6.83%
Return on Capital Employed (ROCE)-0.12
Revenue Per Employee175.77K
Profits Per Employee-83.40K
Employee Count239
Asset Turnover0.14
Inventory Turnover2.36
Valuation Ratios
The current PE Ratio of Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. is ―. Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.’s PEG ratio is 0.04.
PE Ratio―
PS Ratio6.30
PB Ratio2.12
Price to Fair Value2.12
Price to FCF-12.73
Price to Operating Cash Flow26.90
PEG Ratio0.04
Income Statement
In the last 12 months, Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. had revenue of 42.01M and earned -19.93M in profits. Earnings per share was -0.27.
Revenue42.01M
Gross Profit12.99M
Operating Income-20.58M
Pretax Income-23.91M
Net Income-19.93M
EBITDA-7.28M
Earnings Per Share (EPS)-0.27
Cash Flow
In the last 12 months, operating cash flow was 8.48M and capital expenditures -28.04M, giving a free cash flow of -19.56M billion.
Operating Cash Flow8.48M
Free Cash Flow-19.56M
Free Cash Flow per Share-0.26
Dividends & Yields
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.46
52-Week Price Change-43.95%
50-Day Moving Average3.48
200-Day Moving Average3.93
Relative Strength Index (RSI)29.30
Average Volume (3m)65.77K
Important Dates
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. as a current ratio of 0.90, with Debt / Equity ratio of 67.89%
Current Ratio0.90
Quick Ratio0.81
Debt to Market Cap0.30
Net Debt to EBITDA-11.39
Interest Coverage Ratio-5.21
Taxes
In the past 12 months, Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. has paid -3.98M in taxes.
Income Tax-3.98M
Effective Tax Rate0.17
Enterprise Valuation
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. EV to EBITDA ratio is -47.75, with an EV/FCF ratio of -16.71.
EV to Sales8.28
EV to EBITDA-47.75
EV to Free Cash Flow-16.71
EV to Operating Cash Flow48.14
Balance Sheet
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. has zł1.67M in cash and marketable securities with zł84.65M in debt, giving a net cash position of -zł82.97M billion.
Cash & Marketable Securitieszł1.67M
Total Debtzł84.65M
Net Cash-zł82.97M
Net Cash Per Share-zł1.09
Tangible Book Value Per Sharezł2.22
Margins
Gross margin is 52.27%, with operating margin of -48.98%, and net profit margin of -47.45%.
Gross Margin52.27%
Operating Margin-48.98%
Pretax Margin-56.92%
Net Profit Margin-47.45%
EBITDA Margin-17.34%
EBIT Margin-48.98%
Analyst Forecast
The average price target for Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-41.46%
EPS Growth Forecast-357.92%